COMP <GO>
ROIV vs ALNY // FORWARD P/E MULTIPLE
Roivant Sciences Ltd. (NASDAQ) VS. Alnylam Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ROIV 4
— ALNY 6
▲ FORWARD P/E MULTIPLE LEADER: ROIV
LAST: $35.89 (-2.76%) • MKT CAP: $26.66B
forward-pe
28.0x
LAST: $158.00 (-4.24%) • MKT CAP: $22.10B
forward-pe
62.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROIV VS. ALNY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROIV | ALNY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 81.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.00% | 21.30% | -35.30 | ALNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 42.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.80% | 2.00% | -4.80 | ALNY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 13.50% | -73.50 | ALNY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 8.40% | -68.40 | ALNY | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 65.20% | -130.20 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.16 | +22.84 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | ALNY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.3 | 25.8 | +27.50 | ROIV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.00 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 28.0x | 62.3x | -34.30 | ROIV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $26.66B | $22.10B | $4.56B | ROIV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROIV REV | ALNY REV | ROIV GROSS % | ALNY GROSS % | ROIV FCF | ALNY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $3.71B | — | 81.8% | -$758.6M | $465.4M |
| FY 2024 | $29.1M | $2.25B | — | 86.4% | -$844.0M | -$42.6M |
| FY 2023 | $32.7M | $1.83B | — | — | -$766.7M | $21.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROIV // BETA 1.00
ALNY // BETA 1.00